Apellis Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Addition...
January 13 2020 - 12:10PM
Apellis Pharmaceuticals, Inc. (Nasdaq:APLS), a global
biopharmaceutical company pioneering targeted C3 therapies, today
announced the closing of its previously announced underwritten
public offering of common stock, including the exercise in full by
the underwriters of their option to purchase an additional
1,425,000 shares at the public offering price of $37.00 per share.
The exercise of the option to purchase additional shares brought
the total number of shares of common stock sold by Apellis to
10,925,000 shares and increased the amount of gross proceeds,
before deducting underwriting discounts and commissions and
expenses payable by Apellis, to approximately $404.2 million.
Citigroup, J.P. Morgan and Evercore ISI acted as joint
book-running managers for the offering. Cantor Fitzgerald & Co.
and Baird acted as lead managers for the offering.
The shares were offered by Apellis pursuant to an automatically
effective shelf registration statement that was filed with the
Securities and Exchange Commission (“SEC”) on January 7, 2020. This
offering was made only by means of a prospectus and prospectus
supplement that form a part of the registration statement. A final
prospectus supplement relating to and describing the terms of the
offering has been filed with the SEC and may be obtained for free
by visiting the SEC’s website at www.sec.gov. Copies of the final
prospectus supplement and the accompanying prospectus may also be
obtained by contacting: Citigroup Global Markets Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, telephone: 1-800-831-9146; J.P. Morgan Securities LLC,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
Edgewood, NY 11717, telephone: (866) 803-9204; or Evercore Group
L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street,
36th Floor, New York, NY 10055, telephone: (888) 474-0200, or
email: ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell, or a
solicitation of an offer to buy these securities, nor shall there
be any sale of, these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical
company that is committed to leveraging courageous science,
creativity, and compassion to deliver life-changing therapies. By
pioneering targeted C3 therapies, we aim to develop best-in-class
and first-in-class therapies for a broad range of debilitating
diseases that are driven by uncontrolled or excessive activation of
the complement cascade, including those within hematology,
ophthalmology, and nephrology.
Media Contact: Tracy Vineis media@apellis.com
617.420.4839
Investor Contact: Sam Martin / Maghan
Meyers Argot Partnerssam@argotpartners.com
/ maghan@argotpartners.com 212.600.1902
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Apellis Pharmaceuticals (NASDAQ:APLS)
Historical Stock Chart
From Apr 2023 to Apr 2024